Frailty linked to faster decline during lecanemab therapy
Patients with physical frailty worsened 1.52 points per year faster on a dementia severity scale than those without frailty while receiving lecanemab.
Limit: Only 187 patients were included, and the authors called for validation in larger cohorts
Edited by Boris Djordjevic · AgingResearch.News
An observational cohort study followed 187 people with early Alzheimer's disease who began lecanemab at a specialized memory clinic. All tested positive for amyloid, a protein that accumulates in Alzheimer's disease. Researchers assessed physical frailty with a short set of physical performance tests. They also assessed sarcopenia, reduced muscle mass and function.
Physical frailty and sarcopenia were linked to faster worsening on a dementia severity scale, by 1.52 and 1.40 points per year, respectively. Neither was linked to changes on a separate brief cognitive test. People with physical frailty had higher odds of infusion-related reactions than those without frailty, with an adjusted odds ratio of 4.75. Frailty was not linked to amyloid-related abnormalities on brain scans or to stopping treatment.
Why it matters
Alzheimer's disease involves progressive cognitive decline. The authors suggest physical frailty may be a candidate marker for anticipating clinical outcomes during lecanemab therapy.
Caveats
This observational study cannot show that frailty caused faster decline or changed lecanemab's effects. It included 187 patients at one clinic, and the authors called for validation in larger cohorts.
Where the evidence stands
Lecanemab
- 1 lab in 1 country
- 13 trials, 2 with no results posted
- Funder: Japan Society for the Promotion of Science
- 8 of 13 trials sponsored by its developers
- Lecanemab
- Alzheimer's disease
- Sarcopenia
- Infusion-related reactions
- Amyloid-related imaging abnormalities
- Humans
The paper
Korea University Guro Hospital
Aging and Disease, Oct 11, 2026
Comments
Be the first to comment.